- A metabolic enzyme exists in two conformational states: a T (tense) state with low substrate affinity and an R (relaxed) state with high substrate affinity. In the presence of an allosteric activator, the T→R equilibrium shifts toward the R state. Which statement best explains the molecular basis for this cooperative transition?
Answer: The activator stabilizes the R state through favorable binding interactions, lowering the free energy of the R state relative to the T state
Allosteric activators work by binding preferentially to one conformational state (usually R) and stabilizing it through favorable interactions, shifting the T⇌R equilibrium. This follows the Monod-Wyman-Changeux model where ligands shift conformational equilibria. Choice A describes competitive inhibition, not allosteric activation. Choice C incorrectly focuses on catalysis rather than binding equilibrium. Choice D suggests non-specific destabilization rather than selective stabilization.
- An allosteric enzyme shows cooperative substrate binding with a Hill coefficient of 2.5. A pharmaceutical company develops three potential allosteric modulators and tests their effects. Compound A reduces the Hill coefficient to 1.8 while maintaining the same S₀.₅ value. Compound B maintains the Hill coefficient at 2.5 but decreases S₀.₅ by 50%. Compound C reduces the Hill coefficient to 1.0 and decreases S₀.₅ by 75%. Which compound would be most effective at increasing enzyme activity at physiological substrate concentrations that are typically well below S₀.₅?
Answer: Compound C, because both eliminated cooperativity and reduced S₀.₅ maximize low-substrate activity
At substrate concentrations well below S₀.₅, the Hill equation simplifies to Y ≈ [S]^nH/S₀.₅^nH. Compound C combines the largest reduction in S₀.₅ (75% decrease means 4-fold increase in apparent affinity) with elimination of cooperativity (nH = 1), providing the steepest initial slope and highest activity at low [S]. Choice A maintains the same S₀.₅. Choice B has smaller S₀.₅ improvement. Choice D is incorrect because the different S₀.₅ values create significant differences in low-[S] activity.
- Phosphofructokinase-1 (PFK-1), a key regulator of glycolysis, is allosterically inhibited by ATP and activated by AMP and fructose 2,6-bisphosphate (F2,6BP). In a muscle cell during strenuous exercise, ATP is consumed while AMP levels rise sharply. Simultaneously, hormonal signals lead to a high concentration of F2,6BP. Which statement best describes the activity of PFK-1 under these conditions?
Answer: PFK-1 activity will be strongly stimulated, as the potent allosteric activators AMP and F2,6BP effectively overcome the allosteric inhibition by ATP.
This scenario describes a high-energy-demand state. The rise in AMP and the presence of the potent activator F2,6BP are strong signals for glycolysis to proceed rapidly. These activators work by binding to allosteric sites and stabilizing the active R-state of PFK-1. This stabilization is potent enough to overcome the inhibitory effect of ATP (which signals high energy) at its separate allosteric site, leading to a high rate of glycolysis to generate more ATP.
- A tetrameric enzyme exhibits ideal positive cooperativity according to the MWC model. An allosteric activator is added that has an extremely high affinity for the R-state and zero affinity for the T-state. If a saturating concentration of this activator is present, what will the enzyme's kinetic profile with respect to its substrate most likely resemble?
Answer: A hyperbolic curve (Michaelis-Menten kinetics) with a low apparent Km, reflecting high substrate affinity.
When you encounter questions about allosteric enzymes and cooperativity, focus on how binding events affect the equilibrium between conformational states. The MWC (Monod-Wyman-Changeux) model describes enzymes that exist in two states: a low-affinity T-state and a high-affinity R-state, with all subunits transitioning together.
Here's the key insight: when a saturating concentration of activator with exclusive R-state affinity is present, it essentially "locks" all enzyme molecules in the R-state. Since cooperativity arises from the transition between T and R states as substrate binds, eliminating this transition eliminates cooperativity. With all subunits now in the high-affinity R-state, each binding site behaves independently, producing classic Michaelis-Menten (hyperbolic) kinetics with a low apparent Km due to the high substrate affinity of the R-state.
Option A is incorrect because cooperativity is eliminated, not enhanced—there's no sigmoidal curve when the enzyme is locked in one state. Option B misunderstands the R-state's role; the R-state is the active, high-affinity form, not non-productive. Option C fails because while the curve would shift left (lower Km), it loses its sigmoidal shape entirely since cooperativity disappears.
Remember this pattern: allosteric effectors that completely favor one conformational state eliminate cooperativity by removing the equilibrium that creates it. Look for scenarios where "saturating" concentrations of specific-state effectors convert cooperative enzymes into simple Michaelis-Menten systems. - Aspartate transcarbamoylase (ATCase) is a key regulatory enzyme in pyrimidine biosynthesis. It is allosterically inhibited by the pathway's final product, CTP, and allosterically activated by ATP. A mutation in the regulatory subunit of ATCase completely prevents CTP from binding, but the binding of ATP and the substrate aspartate remain unaffected. How will this mutation most likely impact pyrimidine synthesis in a cell with high ATP levels?
Answer: Pyrimidine synthesis will be constitutively high, potentially leading to overproduction, because the primary feedback inhibition loop is abolished.
The role of CTP is to provide negative feedback inhibition, shifting the enzyme toward the less active T-state. The mutation abolishes this inhibition. High ATP levels act as an allosteric activator, promoting the active R-state. Without the opposing effect of CTP, the enzyme will be highly active in the presence of ATP and substrate, leading to a loss of feedback control and potential overproduction of pyrimidines.
- Hemoglobin's cooperative binding of oxygen results in a sigmoidal binding curve. What is the primary physiological advantage of this cooperativity compared to a hypothetical non-cooperative protein with a hyperbolic binding curve and the same P50 value?
Answer: It allows for a much larger fraction of bound oxygen to be delivered to tissues for a given drop in oxygen partial pressure.
The steepness of the sigmoidal curve is the key advantage. In the high pO2 of the lungs, hemoglobin becomes highly saturated. In the lower pO2 of peripheral tissues, the curve drops steeply, meaning hemoglobin's affinity for oxygen decreases sharply, causing it to release a large amount of oxygen. A hyperbolic curve with the same P50 would be less sensitive to this drop in pO2, releasing a smaller percentage of its bound oxygen over the same physiological pressure range. Cooperativity thus makes hemoglobin an efficient oxygen transporter, not just a storage molecule.
- An enzyme with multiple subunits normally displays a sigmoidal velocity versus substrate plot. In the presence of molecule X, the plot remains sigmoidal but is shifted significantly to the right, and the steepness of the curve's rising portion is reduced. Molecule X does not compete with the substrate for binding at the active site. What is the most likely role of molecule X?
Answer: An allosteric inhibitor that stabilizes the T-state and decreases the degree of positive cooperativity.
A rightward shift in a sigmoidal plot indicates an increase in K0.5, meaning a higher substrate concentration is needed for half-saturation. This is characteristic of an inhibitor that stabilizes the low-affinity T-state. The reduced steepness of the curve signifies a decrease in the Hill coefficient (nH), which means the degree of positive cooperativity has been reduced. Since the molecule does not bind the active site, it is an allosteric inhibitor.
- An allosteric enzyme shows the following kinetic behavior: in the absence of effectors, it displays strong positive cooperativity (nH=3.2). When effector molecule Z is added, the enzyme shows typical Michaelis-Menten kinetics (nH=1.0) with no change in Vmax. What is the most likely mechanism by which effector Z influences this enzyme?
Answer: Effector Z functions as an allosteric activator that locks the enzyme in the R state, eliminating the T⇌R equilibrium responsible for cooperativity
The transition from highly cooperative (nH=3.2) to Michaelis-Menten behavior (nH=1.0) with unchanged Vmax indicates that effector Z eliminates cooperativity by stabilizing the high-affinity R state. This prevents the T⇌R transitions that create sigmoidal kinetics. Choice A describes mixed inhibition, which would change Vmax. Choice B is vague about mechanism. Choice D suggests irreversible modification, which contradicts typical allosteric regulation. - The Monod-Wyman-Changeux (MWC) model and the Koshland-Nemethy-Filmer (KNF) model both describe allosteric regulation. Which of the following is a key feature of the KNF (sequential) model that is explicitly forbidden in the MWC (concerted) model?
Answer: The enzyme oligomer can exist in a hybrid state with some subunits in the T conformation and others in the R conformation.
The MWC or 'concerted' model postulates that all subunits of the oligomeric enzyme transition between the T and R states simultaneously; thus, the entire protein is either in the T-state or the R-state. The KNF or 'sequential' model allows for ligand-induced conformational changes in individual subunits, meaning an oligomer can exist in a hybrid state with a mix of T-state and R-state subunits. This existence of hybrid oligomers is a primary distinction forbidden by the MWC model's 'all-or-none' transition rule.
- In the context of allosteric enzyme regulation, which of the following provides the most accurate distinction between a homotropic and a heterotropic effector?
Answer: A homotropic effector is the substrate for the enzyme itself, whereas a heterotropic effector is any regulatory molecule that is not the enzyme's substrate.
When you encounter questions about allosteric regulation, focus on the fundamental definitions that distinguish different types of effectors based on their molecular identity relative to the enzyme's substrate.
Answer D correctly captures the essential distinction: homotropic effectors are the substrate molecules themselves acting as regulatory molecules, while heterotropic effectors are any other molecules (not the substrate) that regulate the enzyme. In homotropic regulation, the substrate binding to one site influences substrate binding at other sites, creating cooperative effects. Heterotropic regulation involves separate regulatory molecules binding to allosteric sites distinct from the active site.
Answer A is incorrect because homotropic effectors aren't always activators - they can show either positive or negative cooperativity. Additionally, heterotropic effectors can be either activators or inhibitors, not just inhibitors.
Answer B misrepresents the kinetic effects. Both homotropic and heterotropic effectors can influence K0.5 (the substrate concentration at half-maximal velocity), and both can potentially affect Vmax depending on the specific regulatory mechanism.
Answer C incorrectly assigns exclusive models to each effector type. Both the concerted (MWC) and sequential (KNF) models can describe either homotropic or heterotropic effects, depending on the specific enzyme and regulatory mechanism involved.
Remember this simple distinction: "homo" means "same" - so homotropic effects involve the same molecule (the substrate) acting as both substrate and effector. "Hetero" means "different" - so heterotropic effects involve different molecules serving as regulators. - An allosteric enzyme is classified as being regulated by a 'K-type' mechanism. A newly discovered allosteric inhibitor for this enzyme is introduced into the assay. Which kinetic parameter is most directly affected by this inhibitor, and how is it expected to change?
Answer: The K0.5 is increased, while the Vmax remains largely unchanged.
Allosteric systems are broadly classified as K-type or V-type. A K-type system is one where the regulators affect the apparent substrate affinity (K0.5) but not the maximal velocity (Vmax). An inhibitor in a K-type system will make it harder for the substrate to bind and/or promote the low-affinity T-state, thereby increasing the substrate concentration required to reach half Vmax (increasing K0.5). A V-type system is one where regulators affect Vmax but not K0.5.
- An enzyme exhibits sigmoidal kinetics with respect to its substrate concentration. A researcher identifies a small molecule that, when added, shifts the substrate concentration required to reach half-maximal velocity (Vmax) to a lower value, without altering Vmax itself. The molecule shows no structural similarity to the substrate. Which statement most accurately describes this molecule and its effect?
Answer: An allosteric activator that preferentially binds to and stabilizes the R-state of the enzyme.
Sigmoidal kinetics are a hallmark of allosteric enzymes with cooperative substrate binding, which exist in equilibrium between a low-affinity T-state and a high-affinity R-state. The molecule lowers the substrate concentration needed for half-saturation (K0.5), indicating it increases the enzyme's apparent affinity for the substrate. Since it is not a substrate analog, it must bind to a distinct allosteric site. By binding to and stabilizing the high-affinity R-state, an allosteric activator shifts the T/R equilibrium toward R, causing this leftward shift in the kinetic curve without changing the maximal velocity.
- A protein kinase is regulated by an intracellular second messenger. The binding of this messenger to a regulatory domain on the kinase causes a conformational change that unblocks the active site, increasing its catalytic activity. This regulation is rapid and its effect is directly proportional to the messenger's concentration. This mechanism is best described as:
Answer: Allosteric activation, where the second messenger functions as a heterotropic positive effector.
When analyzing enzyme regulation mechanisms, focus on how the regulatory molecule interacts with the enzyme and what type of binding site is involved. This question describes a classic allosteric regulation scenario.
The correct answer is D because all the key features of allosteric activation are present: a regulatory molecule (second messenger) binds to a distinct regulatory domain (not the active site), causes a conformational change that enhances activity, and shows proportional response to effector concentration. Since the second messenger is different from the substrate, it's a heterotropic (different molecule) positive effector that increases activity through allosteric mechanisms.
Option A is incorrect because competitive inhibition involves molecules competing for the same active site, but here the second messenger binds to a separate regulatory domain. The regulatory domain isn't competing with substrate—it's enhancing substrate binding when occupied.
Option B is wrong because homotropic cooperativity refers to the substrate itself binding to multiple sites and increasing affinity at other sites (like oxygen binding to hemoglobin). Here, the effector molecule is different from the substrate, making this heterotropic regulation.
Option C is incorrect because covalent modification involves chemical bonds forming or breaking (like phosphorylation/dephosphorylation). The question describes non-covalent binding that's rapidly reversible and concentration-dependent, which is characteristic of allosteric interactions, not covalent modifications.
Remember: Allosteric regulation involves binding at sites distinct from the active site, causing conformational changes. If the regulatory molecule differs from the substrate, it's heterotropic regulation.
- According to the concerted (MWC) model, an allosteric enzyme's conformational equilibrium is described by the allosteric constant, L, where L = [T]/[R]. A particular enzyme has a very large intrinsic value for L. What does this imply about the enzyme's baseline state and the mechanism of an allosteric activator?
Answer: The enzyme predominantly exists in the inactive T-state, and an activator functions by binding to and stabilizing the R-state.
A large value for L ([T]/[R]) means that in the absence of any ligands, the equilibrium heavily favors the T-state (the low-activity conformation). The R-state (high-activity) exists, but at a very low concentration. An allosteric activator functions by binding with high affinity to the R-state. This binding sequesters the R-state from the equilibrium, and by Le Châtelier's principle, pulls the T-to-R equilibrium towards the R-state, increasing the population of active enzyme molecules. The activator does not bind T to convert it; it binds the pre-existing R to stabilize it.
- A multimeric enzyme is analyzed, and its activity is measured as a function of substrate concentration. A subsequent Hill plot of the data yields a Hill coefficient (nH) of 0.8. What can be concluded about the enzyme's binding mechanism?
Answer: The enzyme exhibits negative cooperativity, where substrate binding to one active site decreases substrate affinity at other sites.
The Hill coefficient (nH) quantifies the degree of cooperativity in ligand binding. A value of nH > 1 indicates positive cooperativity. A value of nH = 1 indicates no cooperativity, characteristic of Michaelis-Menten enzymes. A value of nH < 1 indicates negative cooperativity, where the binding of one substrate molecule to a subunit makes it more difficult for other substrate molecules to bind to the remaining empty subunits.
- A dimeric enzyme is allosterically regulated through cooperative substrate binding. A mutation is introduced that disrupts key noncovalent interactions at the interface between the two subunits, but does not affect the catalytic residues within the active site of each individual subunit. What is the most likely consequence of this mutation on the enzyme's overall kinetics?
Answer: The enzyme will likely lose its cooperative binding properties and exhibit hyperbolic, Michaelis-Menten kinetics.
Cooperativity, the phenomenon where the binding of a ligand to one subunit affects the binding properties of other subunits, requires communication between the subunits. This communication is mediated by the structural interactions at the subunit interface. If these interactions are disrupted, the subunits can no longer effectively signal their conformational state to one another. As a result, they behave as independent units, and the overall kinetics will revert to the non-cooperative, hyperbolic profile characteristic of Michaelis-Menten enzymes. The intrinsic activity of each active site is stated to be unaffected.
- Glycogen phosphorylase, which catalyzes the first step of glycogenolysis, is an allosterically regulated enzyme. It is activated by AMP and inhibited by ATP and glucose-6-phosphate. Considering the enzyme's metabolic role, what is the most logical explanation for this regulatory scheme?
Answer: High ATP and glucose-6-phosphate indicate a high-energy state with sufficient glucose, so further glycogen breakdown is inhibited.
Glycogen phosphorylase mobilizes glucose from glycogen stores. This process is needed when the cell requires energy. AMP is a signal of low energy charge, so its activation of the enzyme makes physiological sense. Conversely, ATP (high energy charge) and glucose-6-phosphate (a product of glycogenolysis and the first intermediate in glycolysis) are signals that the cell has sufficient energy and glucose. Their role as allosteric inhibitors provides feedback to shut down glycogen breakdown when it is not needed.
- An allosteric enzyme is regulated by molecule Y, which acts as a V-type inhibitor. A site-directed mutation is made in the allosteric binding site for Y, completely abolishing its ability to bind. The mutation has no other effect on the enzyme's structure or its intrinsic catalytic activity. If this mutant enzyme is assayed in the presence of high concentrations of molecule Y, how will its kinetic parameters compare to the wild-type enzyme assayed in the complete absence of molecule Y?
Answer: The mutant's kinetic profile will be nearly identical to the wild-type's profile.
The mutant enzyme cannot bind the inhibitor (molecule Y). Therefore, even in the presence of high concentrations of Y, the mutant enzyme will remain in its unregulated, active state. The wild-type enzyme in the absence of the inhibitor Y is also in its unregulated, active state. Since the mutation is stated to have no other effect on the enzyme's function, the kinetic behavior of the mutant (even with Y present) will be virtually identical to the kinetic behavior of the uninhibited wild-type enzyme.
- An allosteric enzyme in a metabolic pathway is regulated by both ATP (negative effector) and AMP (positive effector). Under cellular conditions where [ATP] = 5 mM, [AMP] = 0.1 mM, and [substrate] = 2 mM, the enzyme operates at 30% of its maximum velocity. If cellular stress causes [ATP] to drop to 1 mM and [AMP] to rise to 1 mM while substrate concentration remains constant, what would be the most likely effect on enzyme velocity?
Answer: Velocity increases dramatically to approximately 75-85% of maximum due to the combined relief of ATP inhibition and strong AMP activation
The 5-fold decrease in ATP concentration removes significant negative allosteric inhibition, while the 10-fold increase in AMP provides strong positive allosteric activation. These effects are synergistic, not competitive, as they likely bind to different allosteric sites. The large magnitude of both changes would dramatically increase enzyme activity. Choice A underestimates the AMP effect. Choice C incorrectly suggests the effects cancel. Choice D incorrectly predicts inhibition from high AMP.
